Affimed
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Affimed and buy or sell other stocks, ETFs, and their options commission-free!About AFMDQ
Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs.
CEOShawn M. Leland
CEOShawn M. Leland
Employees78
Employees78
HeadquartersMannheim, Baden Wuerttemberg
HeadquartersMannheim, Baden Wuerttemberg
Founded2000
Founded2000
Employees78
Employees78
AFMDQ Key Statistics
Market cap1.52K
Market cap1.52K
Price-Earnings ratio—
Price-Earnings ratio—
Dividend yield—
Dividend yield—
Average volume12.17K
Average volume12.17K
High today$0.0001
High today$0.0001
Low today$0.0001
Low today$0.0001
Open price$0.0001
Open price$0.0001
Volume58.40K
Volume58.40K
52 Week high$2.21
52 Week high$2.21
52 Week low$0.00
52 Week low$0.00
Stock Snapshot
Affimed(AFMDQ) stock is priced at $0.00, giving the company a market capitalization of 1.52K.
On 2025-12-16, Affimed(AFMDQ) stock traded between a low of $0.00 and a high of $0.00. Shares are currently priced at $0.00, which is 0.0% above the low and 0.0% below the high.
The Affimed(AFMDQ)'s current trading volume is 58.4K, compared to an average daily volume of 12.17K.
In the last year, Affimed(AFMDQ) shares hit a 52-week high of $2.21 and a 52-week low of $0.00.
In the last year, Affimed(AFMDQ) shares hit a 52-week high of $2.21 and a 52-week low of $0.00.
People also own
Based on the portfolios of people who own AFMDQ. This list is generated using Robinhood data, and it’s not a recommendation.